- 4-AcO-DMT
- 4-Acetoxy-N,N-dimethyltryptamine
- PSOA
- Psilacetin
Nichols, DE; Frescas, SP. Improvements to the synthesis of psilocybin and a facile method for preparing the O-acetyl prodrug of psilocin. Synthesis, 1 Jun 1999, 1999, 935–938. 1.5 MB. https://doi.org/10.1055/s-1999-3490 #2 NMR
Chadeayne, AR; Golen, JA; Manke, DR. The crystal structure of 4-AcO-DMT fumarate. Psychedelic Sci. Rev., 25 Mar 2019, 13. 1.5 MB. #4-AcO-DMT other
Meyers-Riggs, B. 4-Hydroxy tryptamines. countyourculture, countyourculture: rational exploration of the underground, 7 Jul 2012.
Chapman, SJ. PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra. BLOTTER, 1 Mar 2018, 3 (1). 1.2 MB. https://doi.org/10.16889/isomerdesign-5
Chapman, SJ. PeakAL: Protons I Have Known and Loved, Too — Another Fifty Shades of Grey-Market Spectra. Supplementary Data. BLOTTER, 1 Mar 2018, 3 (1). 5.7 MB. https://doi.org/10.16889/isomerdesign-5-supp
EMCDDA. New drugs in Europe, 2009, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2010. 321 kB. #13
Geiger, HA; Wurst, MG; Daniels, RN. DARK classics in chemical neuroscience: Psilocybin. ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2438–2447. 580 kB. https://doi.org/10.1021/acschemneuro.8b00186 #20
Sexton, JD; Nichols, CD; Hendricks, PS. Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics. Front. Psychiatry, 11 Feb 2020, 10 (896). 529 kB. https://doi.org/10.3389/fpsyt.2019.00896 #4-AcO-DMT
Elliott, SP; Holdbrook, T; Brandt, SD. Prodrugs of new psychoactive substances (NPS): A new challenge. J. Forensic Sci., 13 Jan 2020, 65 (3), 913-920. 815 kB. https://doi.org/10.1111/1556-4029.14268 #4-AcO-DMT MS,UV
Chadeayne, AR; Golen, JA; Manke, DR. Bis(4-acetoxy-N,N-dimethyltryptammonium) fumarate: A new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrug. Acta Crystallogr. E, 1 Jun 2019, 75 (6), 900–902. 597 kB. https://doi.org/10.1107/S2056989019007370 #Psilacetin other
Palamar, JJ; Acosta, P. A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines. Hum. Psychopharmacol. Clin. Exp., 1 Jan 2020, 35 (1), e2719. 764 kB. https://doi.org/10.1002/hup.2719 #4-AcO-DMT
Chadeayne, AR; Pham, DNK; Reid, BG; Golen, JA; Manke, DR. Active metabolite of aeruginascin (4-hydroxy-N,N,N-trimethyltryptamine): Synthesis, structure, and serotonergic binding affinity. ACS Omega, 14 Jul 2020, 5 (27), 16940–16943. 2.8 MB. https://doi.org/10.1021/acsomega.0c02208 #psilacetin NMR,other
Klein, AK; Chatha, M; Laskowski, LJ; Anderson, EI; Brandt, SD; Chapman, SJ; McCorvy, JD; Halberstadt, AL. Investigation of the structure–activity relationships of psilocybin analogues. ACS Pharmacol. Transl. Sci., 9 Apr 2021, 4 (2), 533-542. 1.9 MB. https://doi.org/10.1021/acsptsci.0c00176 #4-AcO-DMT
Glatfelter, GC; Pottie, E; Partilla, JS; Sherwood, AM; Kaylo, K; Pham, DNK; Naeem, M; Sammeta, VR; DeBoer, S; Golen, JA; Hulley, EB; Stove, CP; Chadeayne, AR; Manke, DR; Baumann, MH. Structure–activity relationships for psilocybin, baeocystin, aeruginascin, and related analogues to produce pharmacological effects in mice. ACS Pharmacol. Transl. Sci., 11 Nov 2022, 5 (11), 1181–1196. 4.8 MB. https://doi.org/10.1021/acsptsci.2c00177 #Psilacetin MS,NMR,other